Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-EC2115 PET imaging in COPD
NCT03494114Phase 1Terminated
- Sponsor
- Vanderbilt University Medical Center
- Start
- Nov 2018
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Ga-EC2115 in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Vanderbilt University Medical Center. Primary endpoint: Correlation between PET signal and inflammation in bronchoalveolar lavage at 1 day. Started Nov 2018; status: terminated.
02
Drugs
Ga-EC2115
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03494114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03494114.